Lumee™ Glucose

About Profusa

Profusa is pioneering a novel class of continuous monitoring biosensors designed to overcome the fundamental biological challenge of foreign body rejection. Its core technology is an injectable hydrogel microsensor, smaller than a grain of rice, which integrates with tissue and functions for up to 9+ months, enabling long-term, calibration-free monitoring of oxygen, glucose, and other analytes. Backed by over $100M in investment, including significant non-dilutive funding from DARPA and the NIH, and protected by 85 global patents, the company is advancing its Lumee™ Oxygen platform toward a CE Mark target in 2026. Profusa's integrated system combines the sensor with a reusable optical reader and an AI-driven data platform, positioning it to address massive markets in diabetes care, wound management, and remote patient monitoring.

Therapeutic Areas